Murphy Canyon Acquisition Corp. Completes Business Combination with Conduit Pharmaceuticals

Big Cypress Acquisition Corp. Completes Business Combination with SAB Biotherapeutics

October 20, 2021

Biotechnology

Big Cypress Acquisition Corp., a Nasdaq-listed special purpose acquisition company, received shareholder approval to complete a business combination with clinical-stage biopharmaceutical company SAB Biotherapeutics. Upon closing, the combined company will be named SAB Biotherapeutics, Inc. and its common stock and warrants are expected to trade on Nasdaq, providing SAB with public-market capital to advance its antibody immunotherapy platform and clinical programs.

Sun Pharmaceutical Industries Acquires Concert Pharmaceuticals

January 19, 2023

Biotechnology

Sun Pharmaceutical Industries Limited agreed to acquire all outstanding shares of Concert Pharmaceuticals, Inc. via a tender offer for $8.00 per share (approximately $576 million equity value) plus a non-tradeable contingent value right (CVR) of up to $3.50 per share tied to deuruxolitinib sales milestones. The deal adds Concert's late-stage JAK1/2 inhibitor deuruxolitinib for Alopecia Areata to Sun Pharma's global dermatology franchise; Sun Pharma intends to pursue an NDA submission in H1 2023 and expected close was Q1 2023, subject to tender conditions and regulatory approvals.

Mountain Crest Acquisition Corp II Completes Business Combination with Better Therapeutics

October 29, 2021

Healthcare Services

Mountain Crest Acquisition Corp II completed a business combination with Better Therapeutics, taking the prescription digital therapeutics company public on Nasdaq under the ticker BTTX. The transaction generated approximately $70 million in gross proceeds (including a PIPE led by Farallon Capital Management, RS Investments, Sectoral Asset Management and Monashee Investment Management) and included a contingent credit facility from Hercules Capital to fund clinical development and regulatory efforts for Better Therapeutics' lead product, BT-001.

Permira Makes Substantial Growth Investment in PharmaCord

June 6, 2024

Healthcare Services

Permira (via a company backed by Permira funds) has signed a definitive agreement to make a substantial growth investment in PharmaCord, a Jeffersonville, Indiana-based tech-enabled patient services provider for specialty pharmaceuticals. Founder and CEO Nitin Sahney and the management team will remain significant investors and operators; terms were not disclosed and the deal is expected to close by Q4 2024.

Ampersand Capital Partners Acquires Purna Pharmaceuticals

February 12, 2026

Pharmaceuticals

Ampersand Capital Partners acquired Purna Pharmaceuticals, a Belgian contract development and manufacturing provider of liquid and semi-solid pharmaceutical dosage forms. The investment positions Purna to collaborate with Ampersand portfolio company MedPharm to create a trans‑Atlantic topical and transdermal development and manufacturing offering; Creafund, Purna's prior investor, supported the company for more than a decade and was referenced in the transaction announcement.

Inland Pipe Rehabilitation Acquires Murphy Pipeline Contractors

October 1, 2020

Infrastructure

Inland Pipe Rehabilitation (IPR), a portfolio company of an investment affiliate of J.F. Lehman & Company (JFLCO), has completed the acquisition of Murphy Pipeline Contractors. The deal adds Murphy's trenchless potable water rehabilitation capabilities (including its CompressionFit solution and pre-chlorinated pipe bursting) to IPR's existing wastewater and storm-water offerings as a complementary add-on to expand capabilities and national reach.